Loading...
ROCO
6649
Market cap50mUSD
Jul 09, Last price  
38.85TWD
1D
-1.40%
1Q
-4.07%
IPO
-48.62%
Name

Taiwan Biomaterial Co Ltd

Chart & Performance

D1W1MN
ROCO:6649 chart
P/E
27.69
P/S
7.40
EPS
1.40
Div Yield, %
Shrs. gr., 5y
4.27%
Rev. gr., 5y
64.90%
Revenues
220m
+128.22%
2,059,0001,879,0001,004,00016,543,00018,075,00041,674,000127,306,00072,838,00096,574,000220,401,000
Net income
59m
P
-32,601,000-49,629,000-60,541,000-71,299,000-55,366,000-47,442,00033,755,000-10,130,000-1,732,00058,926,000
CFO
49m
+164.68%
-32,054,000-42,268,000-60,720,000-65,439,000-44,398,000-32,009,00035,025,000-10,163,00018,427,00048,772,000
Dividend
Aug 09, 20230.2 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Taiwan Biomaterial Co., Ltd., established in 2010 and based in Zhubei, Taiwan, focuses on the innovation, development, and commercialization of medical devices throughout Taiwan. Their product offerings include Foamagen, a pioneering dural substitute characterized by its foamy structure. The company also provides a sophisticated negative pressure catheter system engineered for stroke intervention, which efficiently suctions and removes cerebrovascular embolism blood clots, accompanied by a specialized nickel-titanium guidewire essential for guiding intricate neurovascular procedures. Additionally, Taiwan Biomaterial develops advanced tissue repair and regeneration solutions specifically targeting the treatment of early-stage osteoarthritis.
IPO date
Aug 29, 2017
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT